WO1999014345A2 - Arzneimittel zur therapie einer manifesten lyme-borreliose - Google Patents
Arzneimittel zur therapie einer manifesten lyme-borreliose Download PDFInfo
- Publication number
- WO1999014345A2 WO1999014345A2 PCT/EP1998/005852 EP9805852W WO9914345A2 WO 1999014345 A2 WO1999014345 A2 WO 1999014345A2 EP 9805852 W EP9805852 W EP 9805852W WO 9914345 A2 WO9914345 A2 WO 9914345A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ospc
- burgdorferi
- specific
- antibody
- active ingredient
- Prior art date
Links
- 208000016604 Lyme disease Diseases 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims description 5
- 108700023315 OspC Proteins 0.000 claims abstract description 72
- 241000589969 Borreliella burgdorferi Species 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 101710134191 24 kDa antigen Proteins 0.000 claims abstract description 13
- 241000699670 Mus sp. Species 0.000 claims description 48
- 210000002966 serum Anatomy 0.000 claims description 30
- 241000589970 Spirochaetales Species 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 206010003246 arthritis Diseases 0.000 claims description 15
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 13
- 230000001717 pathogenic effect Effects 0.000 claims description 11
- 206010062746 Carditis Diseases 0.000 claims description 6
- 208000009525 Myocarditis Diseases 0.000 claims description 6
- 208000021646 inflammation of heart layer Diseases 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims 4
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 101100240595 Mus musculus Nipal4 gene Proteins 0.000 claims 1
- 108700006640 OspA Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 description 41
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000001503 joint Anatomy 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 7
- 210000004201 immune sera Anatomy 0.000 description 7
- 229940042743 immune sera Drugs 0.000 description 7
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000448699 Borrelia burgdorferi ZS7 Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 206010052057 Neuroborreliosis Diseases 0.000 description 1
- 208000035056 Tick-Borne disease Diseases 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000016523 tick-borne infectious disease Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to a pharmaceutical composition for the treatment of Lyme disease and a vaccine against Lyme disease, as well as a method for obtaining an active substance for treating Lyme disease and a method for obtaining a vaccine for Lyme disease.
- Lyme disease is a tick-borne infectious disease caused by Spirochete Borrelia burgdorferi.
- the disease is a chronic progressive infection that affects many organs, such as the skin, central and peripheral nervous system, heart, liver, kidney, musculoskeletal system, and joints.
- Various symptoms such as acute arthritis and neuroborreliosis, can disappear spontaneously, but usually recur episodically.
- Spirochetes have been isolated from untreated patients repeatedly, and there are numerous signs of persistent infections even after antibiotic therapy. Since reliable treatment of this disease through therapy with antibiotics is therefore difficult, great efforts are made to research the pathogen itself and the host's immune response to infection with B. burgdorferi.
- a high titer of antibodies against B. burgdorferi is usually found in the course of the infection, but this does not provide any protection against the infection.
- OspA outer surface lipoprotein A
- B. burgdorferi could be an effective vaccine for the prophylaxis of Lyme disease (EP 0 41 8 827).
- Laboratory studies in mice have shown that extensive protection against a disease in infection can be obtained by OspA-specific antibodies (Schaible et al., Proc. Natl. Acad. Sci. USA 87 (1 990), 3768-3772) .
- these antibodies are only effective if they are present at the time the pathogen is transmitted.
- One reason for this could be that OspA is mainly expressed on spirochetes in ticks, but is no longer expressed after transmission to a mammalian host.
- OspA-specific antibodies can be used to prevent the transmission of the disease, but are ineffective and therefore unsuitable for therapeutic applications for the treatment of the outbreak.
- Recent studies show that after active immunization with recombinant OspC, mice could be protected against a tick-borne infection (Preac-Mursic et al., Infection 20 (1 992), 342-349; RD Gilmore et al., Infect. Immun. 64 (1,996), 2234-2239).
- the immunization protocol used there does not lead to the elimination of infectious spirochetes from the vector, as has been shown by OspA-specific antibodies.
- the invention was therefore based on the object of providing a medicament for the treatment of Lyme disease.
- a pharmaceutical composition for the treatment of Lyme disease which is characterized in that it comprises as an active ingredient an antibody which is specific for the 24 kDa antigen (OspC) from B. burgdorferi.
- OspC 24 kDa antigen
- the pharmaceutical composition for the treatment of Lyme disease preferably comprises, as an active ingredient, an antibody which is specific for the 24 kDa antigen (OspC) from B. burgdorferi and which is shown in SEQ ID NO. 2 sequence shown.
- FIG. 1 shows a Western blot analysis of NMS and IS, which were used for passive immunization of C. B.-1 7 scid mice.
- Lane 1 shows a standard of mouse mAbs against Hsp70 (70 kDa), Hsp60 (60 kDa), Flagellin (41 kDa), OspB (34 kDa), OspA (31 kDa), OspC (24 kDa), pLA7 (20 kDa) and p7.5 (7.5 kDa).
- Lane 2 NMS collected from naive BALB / c mice.
- Lane 3 Polyclonal immune serum, formed in BALB / c mice, immunized with rLip-OspA in ABM2 adjuvant.
- Lane 4 Polyclonal IS generated in BALB / c mice immunized with rOspC in ABM2 adjuvant as described herein.
- burgdorferi-specific (IgG) and OspC-specific antibodies (IgM and IgG) in sera from individual mice were determined by ELISA using either whole cell lysates (B. burgdorferi strain ZS7) or rOspC (ZS7) Substrates examined.
- the data represent the mean of individual serum samples examined (AKR / N and C57BL / c: 10 mice / group; BALB / c: 7 mice; A).
- Correlation between serum levels of total B. Burgdor feri-specific IgG antibodies, OspC-specific IgG antibodies (day 23 pi) and the ability to recultivate spirochetes from ear tissue (day 90 pi) were analyzed by correlation assay (B).
- FIG. 3 shows the DNA sequence and the protein sequence of the 24 kDa antigen (OspC) from B. burgdorferi (SEQ ID NO. 2)
- FIG. 4 shows the construction of the plasmid pG OspC-ZS, which contains the OspC gene.
- mice were subcutaneously (sc) with 1 ⁇ 10 3 low-passage (two to four in vitro passages) organisms B. burgdorferi of the strain ZS7 (Schaible et al., Proc. Natl. Acad. Sci. USA 87 (1 990), 3768-3772) vaccinated in the tail.
- a B. burgdorferi strain ZS7, a glutathione-S-transferase OspC fusion protein (rOspC) was prepared using known techniques (R. Wallich et al., Infect. Immun. 64 (1,995), 3327-3353).
- mice were inoculated with either 10 ⁇ g rLip-OspA or 10 ⁇ g rOspC in 1 00 / vl ABM2 adjuvant (Sebak, Aldenbach, Germany) and injected twice with the same antigen preparation
- the immune serum was collected over a period of approximately 2 months after the last refreshment and contained the following concentrations of OspA or OspC-specific antibodies (Ak), as with an ELISA using rLip-OspA or rOspC as Substrate was determined: Anti-OspA IS, 3.2 mg / ml or Anti-OspC IS, 300 / yg / ml.
- Normal mouse serum (NMS) was collected from naive BALB / c mice. The specificities the immune sera and NMS generated were verified by Western blot analysis.
- Serum antibodies against B. burgdorferi OspA or OspC were quantified by a solid phase ELISA as described in the prior art (Kramer et al., Immunobiol. 1 81 (1 990), 357-366), 1 ⁇ g / ml total cell lysate B. burgdorferi, strain ZS7, rLip-OspA (ZS7) or rOspC (ZS7) were used as substrates.
- Western blot analysis was carried out as described in the prior art (MM Simon et al., J. Infect. Dis. 1 64 (1 991), 1 23-1 32) using a total cell lysate from B. burgdorferi Strain ZS7 performed as an antigen preparation.
- mice 6-8 week old female CB-17 scid mice were injected intraperitoneally (ip) with either an OspA or an OspC-reactive polyclonal immune serum 1 hour before infection. Control mice received 100 // I NMS. For infection, the mice were injected into the tail with 1 ⁇ 10 3 B. burgdorferi ZS7 organisms.
- scid mice were first infected with 1 ⁇ 10 3 ZS7 spirochetes (sc), and then they were repeatedly administered (four times at 3 to 4 day intervals) different amounts of polyclonal immune serum, which was either OspA or Ospc specific (ip), starting on day 1 0, 1 9 or 60 after infection (pi).
- the animals were evaluated for the development of clinical arthritis in the tibiotarsal joints observed.
- the hardness of arthritis in the right and left tibiotarsal joints was assessed as follows: 4- 4-, severe; + moderately difficult; ⁇ , mild swelling; ( ⁇ ), redness; -, no clinical signs.
- mice were examined for the presence of spirochetes by culturing ear tissue samples, following the procedure described in the prior art (Sinsky et al., J. Clin. Microbiol. 27 (1 989), 1 723- 1 727).
- mice were sacrificed at the times indicated after the infection.
- the tibiotarsal joint, the heart, the liver and the muscles adjacent to the tibiotarsal joint were fixed in 10% formaldehyde, embedded in paraffin and stained with hematoxylin and eosin.
- the inflamed lesions were rated as follows: 4- 4- 4-, very severe; 4- 4-, difficult; 4-, moderate; ⁇ , mild; -, no.
- OspC-specific IgM antibodies were first detectable on the 4th day after the infection, peaked on the 1st day after the infection and then decreased to baseline values on the 24th day after the infection. OspC-specific IgG antibodies were first observed on day 1 pi with a peak on day 23 pi (maximum values for AKR / N, C57BL / 6: about 8 // g / ml; BALB / c: about 3 ⁇ g / ml).
- Antibody titers in AKR / N and C57BL / 6 mice decreased over time, but remained at detectable levels (approximately 3 // g / ml) up to 90 days pi.
- BALB / c mice formed lower levels of OspC-specific IgG antibodies in the early phase of infection, but serum titers increased over time after infection.
- mice that received immune serum that either for OspC or OspA (3 ⁇ g specific antibodies / mouse) 1 hour before infection showed no pathological changes in any of the four organs when examined on day 45 pi.
- mice that received an immune serum directed against OspC (10 ⁇ g specific antibodies / mouse) on the 10th or 19th day after the inoculation showed, if at all, only slight inflamed lesions in joints, heart, liver and muscle.
- immune serum directed against OspA (10 ⁇ g specific antibody / mouse) had no effect on the development or progression of inflammation in the affected organs (day 1 9 pi).
- OspC-GST fusion protein Production of OspC-GST fusion protein and purification of rec.
- OspC-GST Cleavage of OspC-GST using thrombin and purification.
- four OspC-GST protein preparations were digested with thrombin protease overnight and OspC from GST via a glutation Seph. 4B column separated.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98946455A EP1015610A2 (de) | 1997-09-16 | 1998-09-15 | Arzneimittel zur therapie einer manifesten lyme-borreliose |
AU93485/98A AU9348598A (en) | 1997-09-16 | 1998-09-15 | Medicament for treating a manifested lyme disease |
US09/508,096 US6761891B1 (en) | 1997-09-16 | 1998-09-15 | Medicament for treating a manifested lyme disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19740735.8 | 1997-09-16 | ||
DE19740735A DE19740735A1 (de) | 1997-09-16 | 1997-09-16 | Arzneimittel zur Therapie einer manifesten Lyme-Borreliose |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999014345A2 true WO1999014345A2 (de) | 1999-03-25 |
WO1999014345A3 WO1999014345A3 (de) | 1999-05-14 |
Family
ID=7842542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/005852 WO1999014345A2 (de) | 1997-09-16 | 1998-09-15 | Arzneimittel zur therapie einer manifesten lyme-borreliose |
Country Status (5)
Country | Link |
---|---|
US (1) | US6761891B1 (de) |
EP (1) | EP1015610A2 (de) |
AU (1) | AU9348598A (de) |
DE (1) | DE19740735A1 (de) |
WO (1) | WO1999014345A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US7060281B1 (en) | 1999-06-18 | 2006-06-13 | Research Foundation Of The State University Of New York | Groups of barrelia burgdorferi and borrelia afzelii that cause lyme disease in humans |
US8137678B2 (en) | 2006-11-03 | 2012-03-20 | Intervet Inc. | Canine lyme disease vaccine |
US8680236B2 (en) | 2000-08-18 | 2014-03-25 | Brookhaven Sciences Associates, Llc | Altered OspA of borrelia burgdorferi |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
EP2167537A2 (de) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Zusammengestellte verfahren für die analyse und sortierung von proben |
EP2197908A2 (de) | 2007-09-27 | 2010-06-23 | Dako Denmark A/S | Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika |
US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994025596A2 (en) * | 1993-04-29 | 1994-11-10 | Immuno Aktiengesellschaft | IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS |
EP0633028A1 (de) * | 1989-09-19 | 1995-01-11 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Impfstoff gegen die Lyme-Krankheit |
-
1997
- 1997-09-16 DE DE19740735A patent/DE19740735A1/de not_active Withdrawn
-
1998
- 1998-09-15 EP EP98946455A patent/EP1015610A2/de not_active Withdrawn
- 1998-09-15 WO PCT/EP1998/005852 patent/WO1999014345A2/de not_active Application Discontinuation
- 1998-09-15 US US09/508,096 patent/US6761891B1/en not_active Expired - Fee Related
- 1998-09-15 AU AU93485/98A patent/AU9348598A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0633028A1 (de) * | 1989-09-19 | 1995-01-11 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Impfstoff gegen die Lyme-Krankheit |
WO1994025596A2 (en) * | 1993-04-29 | 1994-11-10 | Immuno Aktiengesellschaft | IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS |
Non-Patent Citations (4)
Title |
---|
BARTHOLD S.W. ET AL.: "Protective and arthritis-resolving activity in sera of mice infected with Borrelia burgdorferi" CLINICAL INFECTIOUS DISEASES, Bd. 25, Nr. 1 suppl, Juli 1997, Seiten s9-s17, XP002095353 * |
EDELMAN R.: "The seventh international congress on lyme borreliosis: progress on the development of Lyme disease vaccines" VACCINE, Bd. 15, Nr. 5, April 1997, Seiten 463-464, XP002095354 * |
GILMORE R.D. ET AL. : "Outer surface protein C (OspC), but not p39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC " INFECTION AND IMMUNITY, Bd. 64, Nr. 6, Juni 1996, Seiten 2234-2239, XP002095355 * |
ZHONG W. ET AL.: "Therapeutic passive vaccination against chronic Lyme disease in mice" PNAS, Bd. 94, Nr. 23, 11. November 1997, Seiten 12533-12538, XP002095356 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US7179448B2 (en) | 1993-11-01 | 2007-02-20 | Research Foundation Of The State Of New York | Recombinant constructs of Borrelia burgdorferi |
US7605248B2 (en) | 1993-11-01 | 2009-10-20 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US7060281B1 (en) | 1999-06-18 | 2006-06-13 | Research Foundation Of The State University Of New York | Groups of barrelia burgdorferi and borrelia afzelii that cause lyme disease in humans |
US7582304B2 (en) | 1999-06-18 | 2009-09-01 | Research Foundation Of The State University Of New York | Groups of Borrelia burgdorferi and Borrelia afzelii that cause Lyme Disease in humans |
US8680236B2 (en) | 2000-08-18 | 2014-03-25 | Brookhaven Sciences Associates, Llc | Altered OspA of borrelia burgdorferi |
US8992936B2 (en) | 2000-08-18 | 2015-03-31 | Research Foundation Of The State University Of New York | Altered OspA of Borrelia burgdorferi |
US8137678B2 (en) | 2006-11-03 | 2012-03-20 | Intervet Inc. | Canine lyme disease vaccine |
Also Published As
Publication number | Publication date |
---|---|
EP1015610A2 (de) | 2000-07-05 |
DE19740735A1 (de) | 1999-03-18 |
AU9348598A (en) | 1999-04-05 |
US6761891B1 (en) | 2004-07-13 |
WO1999014345A3 (de) | 1999-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0418827B1 (de) | Impfstoff gegen die Lyme-Krankheit | |
DE69231619T3 (de) | Methode und Zusammensetzung zur Verhütung der Lyme-Krankheit | |
DE69212495T2 (de) | Verfahren und zusammensetzungen im hinblick auf nützliche moraxella catarrhalis antigene | |
DE69334002T2 (de) | Membran-assoziierte immunogene proteine des mycobakterien | |
DE69735191T2 (de) | Verfahren zur Herstellung multivalenter Impfstoffe | |
DE60027890T2 (de) | Streptococcus pneumoniae proteine und impfstoffe | |
DE60031974T2 (de) | Abgeschwächte Mikroorganismen zur Behandlung von Infektionen | |
DE69110082T2 (de) | Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae. | |
WO2000047222A2 (de) | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation | |
EP2102345B1 (de) | Rsv f-protein und seine verwendung | |
DE69034075T2 (de) | Rekombinantes poxvirus und streptokokken enthaltend ein m-protein | |
WO1999014345A2 (de) | Arzneimittel zur therapie einer manifesten lyme-borreliose | |
DE69531186T2 (de) | Antibordetella azellulärer Impfstoff | |
DE69933237T3 (de) | Multikomponentimpfstoff mit mindestens zwei antigenen von haemophilus influenzae | |
DE60033291T2 (de) | Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden | |
DE68927144T2 (de) | Impfstoff gegen Bordetella pertussis | |
DE69633179T2 (de) | Transferrinrezeptorgene | |
DE69617956T2 (de) | Zusammensetzungen, welche adp-ribosyltransferase-aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben | |
DE60030060T2 (de) | Mycoplasma hyopneumoniae- Antigen mhp3, dafür kodierendes Gen und ihre Verwendungen | |
DE3787121T2 (de) | Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen. | |
DE60208854T2 (de) | Attenuierte rekombinante stabile Tollwutvirusmutanten und Lebendimpfstoffe | |
DE60127421T2 (de) | Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen | |
DE60037413T2 (de) | Rekombinante adhesin-proteine aus haemophilus influenzae | |
DE69028785T2 (de) | Neuer impfstoff | |
DE60125507T2 (de) | Nukleinsäuren und Proteine des mph3 Gens aus Mycoplasma hypopneumoniae und deren Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998946455 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998946455 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09508096 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998946455 Country of ref document: EP |